Correction: Does this patient with liver disease have cirrhosis? (JAMA - Journal of the American Medical Association (2012) 307:8 (832-842) DOI: 10.1001/jama.2012.186);Does this patient with liver disease have cirrhosis?

JAMA

Volumn 307, Issue 8, 2012, Pages 832-842

  Udell, Jacob A ^a   Wang, Charlie S ^b,c   Tinmouth, Jill ^b   FitzGerald, J Mark ^d,e   Ayas, Najib T ^d,e   Simel, David L ^f   Schulzer, Michael ^e   Mak, Edwin ^d   Yoshida, Eric M ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c Brantford General Hospital   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ACCURACY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; HEPATOMEGALY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; ADULT; BLOOD; CASE REPORT; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; FEMALE; HEMANGIOMA; HEPATITIS C; JAUNDICE; MALE; META ANALYSIS; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ALANINE TRANSAMINASE; ASCITES; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMANGIOMA; HEPATITIS C; HUMANS; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; PLATELET COUNT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84863118796     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.22120     Document Type: Erratum

References (146)

1. Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am. 2009; 93(4):787-799.
2. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5): 960-967. (Pubitemid 36733754)
3. Centers for Disease Control and Prevention. Chronic Liver Disease or Cirrhosis. http://www.cdc.gov/nchs /fastats/liverdis.htm. Updated January 27, 2012. Accessed April 28, 2008.
4. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005; 9(2):191-211.
5. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 2002; 36(5)(suppl 1):S57-S64. (Pubitemid 35253464)
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-662.
7. Propst A, Propst T, Zangerl G, Ofner D, Judmaier G, Vogel W. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci. 1995;40(8):1805-1815.
8. Gentilini P, Laffi G, La Villa G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol. 1997;92(1):66-72. (Pubitemid 27027031)
9. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922-938. (Pubitemid 47436138)
10. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236. (Pubitemid 43112690)
11. Lebrec D, Vinel JP, Dupas JL. Complications of portal hypertension in adults: a French consensus. Eur J Gastroenterol Hepatol. 2005;17(4):403-410. (Pubitemid 40477509)
12. Lizardi-Cervera J, Almeda P, Guevara L, Uribe M. Hepatic encephalopathy: a review. Ann Hepatol. 2003; 2(3):122-130.
13. Murray KF, Carithers RL Jr. Evaluation of the patient for liver transplantation. Hepatology. 2005; 41(6):1407-1432.
14. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001; 35(2):195-199. (Pubitemid 32803474)
15. Bianchi L. Liver biopsy in elevated liver functions tests? J Hepatol. 2001;35(2):290-294.
16. Quinn PG, Johnston DE. Detection of chronic liver disease. Gastroenterologist. 1997;5(1):58-77.
17. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France. Hepatology. 2000;32(3):477-481.
18. Schöniger-Hekele M, Müller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci. 2006;51(2):338-345.
19. Montazeri G, Estakhri A, Mohamadnejad M, et al. Serum hyaluronate as a noninvasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol. 2005; 5:32.
20. Afdhal NH, Nunes D. Evaluation of liver fibrosis. Am J Gastroenterol. 2004;99(6):1160-1174.
21. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009; 49(3):1017-1044.
22. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med. 2004; 350(16):1646-1654.
23. Gordon GG, Olivo J, Rafil F, Southren AL. Conversion of androgens to estrogens in cirrhosis of the liver. J Clin Endocrinol Metab. 1975;40(6):1018-1026.
24. Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. 8th ed. Philadelphia, PA: Saunders Elsevier; 2006.
25. O'Brien DP, Shearer MJ, Waldron RP, Horgan PG, Given HF. The extent of vitamin K deficiency in patients with cholestatic jaundice. J R Soc Med. 1994; 87(6):320-322. (Pubitemid 24189012)
26. van Dam-Mieras MC, Hemker HC. Half-life time and control frequency of vitamin K-dependent Coagulation factors. Haemostasis. 1983;13(3):201-208.
27. Rodríguez-Vilarrupla A, Fernández M, Bosch J, García-Pagán JC. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol. 2007; 6(1):28-36. (Pubitemid 46407486)
28. Arroyo V, Jiménez W. Complications of cirrhosis, II: renal and circulatory dysfunction. J Hepatol. 2000;32(1)(suppl):157-170.
29. Butterworth RF. Complications of cirrhosis, III: hepatic encephalopathy. J Hepatol. 2000;32(1)(suppl): 171-180. (Pubitemid 30123633)
30. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis. Hepatology. 1988;8(5):1151-1157.
31. Naylor CD. Physical examination of the liver. JAMA. 1994;271(23):1859- 1865. (Pubitemid 24169701)
32. Grover SA, Barkun AN, Sackett DL. Does this patient have splenomegaly? JAMA. 1993;270(18): 2218-2221. (Pubitemid 23323639)
33. Williams JW Jr, Simel DL. Does this patient have ascites? JAMA. 1992;267(19):2645-2648.
34. Myers KA, Farquhar DR. Does this patient have clubbing? JAMA. 2001;286(3):341-347. (Pubitemid 32656165)
35. Ruiz MA, Saab S, Rickman LS. The clinical detection of scleral icterus: observations of multiple examiners. Mil Med. 1997;162(8):560-563. (Pubitemid 27494625)
36. Holzberg M, Walker HK. Terry's nails: revised definition and new correlations. Lancet. 1984;1(8382): 896-899. (Pubitemid 14132399)
37. Terry R. White nails in hepatic cirrhosis. Lancet. 1954;266(6815):757- 759.
38. Perera GA. A note on palmar erythema (socalled liver palms). JAMA. 1942;119(17):1417-1418.
39. Carrella M, Hunter JO, Fazio S, Del Piano C, Bartoli GC. Capillary blood flow to the skin of forearm in cirrhosis. Angiology. 1992;43(12):969-974.
40. Braunstein GD. Gynecomastia. N Engl JMed. 2007; 357(12):1229-1237.
41. Khasnis A, Gokula RM. Spider nevus. J Postgrad Med. 2002;48(4):307-309. (Pubitemid 36305518)
42. Reuben A. Along came a spider. Hepatology. 2002; 35(3):735-736. (Pubitemid 34183986)
43. Talley NJ, O'Connor S. Clinical Examination: A Systematic Guide to Physical Diagnosis. 5th ed. Oxford, England: Churchill Livingstone; 2005.
44. Goldman MP. Optimal management of facial telangiectasia. Am J Clin Dermatol. 2004;5(6): 423-434. (Pubitemid 40175260)
45. Gokula RM, Khasnis A. Asterixis. J Postgrad Med. 2003;49(3):272-275. (Pubitemid 37493424)
46. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA. 2005; 294(15):1944-1956. (Pubitemid 41464696)
47. Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53(6): 2107-2110.
48. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology. 1997;26(3)(suppl 1):57S-61S. (Pubitemid 27388073)
49. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598-607. (Pubitemid 47331757)
50. Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis. J Hepatol. 2005;43(1):2-5.
51. Simel DL. Revisiting the primer on the precision and accuracy of the clinical examination. In: Simel DL, Rennie D, eds. Rational Clinical Examination. New York, NY: McGraw Hill; 2009:15-16.
52. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. West Sussex, England: John Wiley & Sons; 2009.
53. Simel DL, Bossuyt PM. Differences between univariate and bivariate models for summarizing diagnostic accuracy may not be large. J Clin Epidemiol. 2009;62(12):1292-1300.
54. Menke J. Bivariate random-effects metaanalysis of sensitivity and specificity with SAS PROC GLIMMIX. Methods Inf Med. 2010;49(1):54-62, 62-64.
55. Marmo R, Romano M, de Sio I, et al. Decisionmaking model for a noninvasive diagnosis of compensated liver cirrhosis. Ital J Gastroenterol. 1993; 25(1):1-8. (Pubitemid 23074329)
56. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979;67(5): 811-816. (Pubitemid 10218835)
57. Nakamura T, Nakamura S, Suzuki O, Aikawa T, Onodera A, Karoji N. Clinical studies of alcoholic hepatic diseases. Tohoku J Exp Med. 1967;93(2): 179-189.
58. Schenker S, Balint J, Schiff L. Differential diagnosis of jaundice: report of a prospective study of 61 proved cases. Am J Dig Dis. 1962;7:449-463.
59. Hamberg KJ, Carstensen B, Sørensen TI, Eghøje K. Accuracy of clinical diagnosis of cirrhosis among alcohol-abusing men. J Clin Epidemiol. 1996;49 (11):1295-1301. (Pubitemid 26387002)
60. Czaja AJ, Wolf AM, Baggenstoss AH. Clinical assessment of cirrhosis in severe chronic active liver disease. Mayo Clin Proc. 1980;55(6):360-364.
61. Cozzolino G, Lonardo A, Francica G, et al. Differential diagnosis between hepatic cirrhosis and chronic active hepatitis. Am J Gastroenterol. 1983;78(7): 442-445.
62. Romagnuolo J, Jhangri GS, Jewell LD, Bain VG. Predicting the liver histology in chronic hepatitis C. Am J Gastroenterol. 2001;96(11):3165-3174.
63. Bain VG, Bonacini M, Govindarajan S, et al. A multicentre study of the usefulness of liver biopsy in hepatitis C. J Viral Hepat. 2004;11(4):375-382. (Pubitemid 38961883)
64. Gordon A, Bailey MJ, Gibson PR, Roberts SK. Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20(6):825-832. (Pubitemid 40897162)
65. Renou C, Muller P, Jouve E, et al. Revelance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus. Am J Gastroenterol. 2001;96(5):1657-1659. (Pubitemid 32455122)
66. Beaton M, Guyader D, Deugnier Y, et al. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology. 2002;36(3):673-678. (Pubitemid 34977178)
67. Poynard T, Bedossa P. Age and platelet count. J Viral Hepat. 1997;4(3):199-208.
68. Schneider AR, Teuber G, Paul K, et al. Patient age i s a strong independent predictor of 13Caminopyrine breath test results. Clin Exp Pharmacol Physiol. 2006;33(4):300-304.
69. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med. 2005;6(6):375-378. (Pubitemid 41723304)
70. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526. (Pubitemid 36919874)
71. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C. Hepatology. 2002;36(4 pt 1):973-977.
72. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005;40(7):867-872. (Pubitemid 40978865)
73. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST /ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998; 93(1):44-48. (Pubitemid 29065511)
74. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or=1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci. 1998;43(9):2156-2159.
75. Anderson FH, Zeng L, Rock NR, Yoshida EM. An assessment of the clinical utility of serum ALT and AST in chronic hepatitis C. Hepatol Res. 2000;18(1): 63-71. (Pubitemid 30330696)
76. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology. 1997;113(5):1609-1616. (Pubitemid 27461247)
77. Croquet V, Vuillemin E, Ternisien C, et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol. 2002;14(10): 1133-1141. (Pubitemid 35178775)
78. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr. 2005;40(5):538-544. (Pubitemid 41669157)
79. McCormick PA, Nolan N. Palpable epigastric liver as a physical sign of cirrhosis. Eur J Gastroenterol Hepatol. 2004;16(12):1331-1334. (Pubitemid 39627534)
80. Niederau C, Lange S, Frühauf M, Thiel A. Cutaneous signs of liver disease. Liver Int. 2008;28 (5):659-666.
81. Cioni G, Tincani E, D'Alimonte P, et al. Relevance of reduced portal flow velocity, low platelet count and enlarged spleen diameter in the noninvasive diagnosis of compensated liver cirrhosis. Eur J Med. 1993;2(7):408-410. (Pubitemid 23267317)
82. Hay CR, Preston FE, Triger DR, et al. Predictive markers of chronic liver disease in hemophilia. Blood. 1987;69(6):1595-1599. (Pubitemid 17091611)
83. Lashner BA, Jonas RB, Tang HS, Evans AA, Ozeran SE, Baker AL. Chronic hepatitis. Am J Med. 1988; 85(5):609-614.
84. Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology. 1989;9(2):193-197. (Pubitemid 19063300)
85. Pagliaro L, Rinaldi F, Craxi A, et al. Predictive value of clinical, laparoscopic and histologic indicators of cirrhosis. Ital J Gastroenterol. 1982;14:166-168. (Pubitemid 13244429)
86. Rankin JG, Orrego-Matte H, Deschênes J, et al. Alcoholic liver disease. Alcohol Clin Exp Res. 1978; 2(4):327-338.
87. Custro N, Carroccio A, Ganci A, et al. Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab. 2001;27(4 pt 1):476-481. (Pubitemid 32852456)
88. Andriulli A, Festa V, Leandro G, Rizzetto M. Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection. Dig Dis Sci. 2001;46(7): 1409-1415. (Pubitemid 32652609)
89. Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol. 2000;95(9):2328-2332.
90. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase:alanine aminotransferase ratio in chronic hepatitis C infection. J Gastroenterol Hepatol. 2000;15(4):386-390. (Pubitemid 30262205)
91. Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci. 1999;44(6):1249-1253. (Pubitemid 29297237)
92. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84(5):1513-1517. (Pubitemid 30644245)
93. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1997; 92(8):1302-1304. (Pubitemid 27328588)
94. Mistry FP, Karnad DR, Abraham P, Bhatia SJ. A scoring system to differentiate cirrhotic from noncirrhotic portal hypertension. Indian J Gastroenterol. 1991;10(3):82-85.
95. Goldberg S, Mendenhall C, Anderson S, et al. The significance of clinically mild alcoholic hepatitis. Am J Gastroenterol. 1986;81(11):1029-1034.
96. Macías J, Girón-González JA, González-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple noninvasive indexes. Gut. 2006; 55(3):409-414. (Pubitemid 43268282)
97. Iacobellis A, Fusilli S, Mangia A, et al. Ultrasonographic and biochemical parameters in the noninvasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. Aliment Pharmacol Ther. 2005; 22(9):769-774. (Pubitemid 41564355)
98. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005; 41(6):1376-1382. (Pubitemid 40770291)
99. Iacobellis A, Mangia A, Leandro G, et al. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. Am J Gastroenterol. 2005;100(4):868-873. (Pubitemid 40592381)
100. Braden B, Faust D, Sarrazin U, et al. 13Cmethacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2005;21(2):179-185. (Pubitemid 40222971)
101. Quereda C, Moreno S, Moreno L, et al. The role of liver biopsy in the management of chronic hepatitis C in patients infected with the human immunodeficiency virus. Hum Pathol. 2004;35(9):1083-1087. (Pubitemid 39165339)
102. Aubé C, Winkfield B, Oberti F, et al. New Doppler ultrasound signs improve the noninvasive diagnosis of cirrhosis or severe liver fibrosis. Eur J Gastroenterol Hepatol. 2004;16(8):743-751. (Pubitemid 39062565)
103. El-Gindy I, El Rahman AT, El-Alim MA, Zaki SS. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as noninvasive markers of hepatic fibrosis in patients with HCV related chronic liver disease. Egypt J Immunol. 2003;10(1):27-35.
104. Kichian K, McLean R, Gramlich LM, Bailey RJ, Bain VG. Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol. 2003;17(1):38-42. (Pubitemid 36322210)
105. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virusrelated chronic liver disease. Arch Intern Med. 2003; 163(2):218-224. (Pubitemid 36120190)
106. Kaul V, Friedenberg FK, Braitman LE, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol. 2002;97(10):2623-2628.
107. Luo JC, Hwang SJ, Chang FY, et al. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatogastroenterology. 2002;49(44):478-481.
108. Boeker KH, Haberkorn CI, Michels D, et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta. 2002;316(1-2):71-81. (Pubitemid 34028190)
109. Saadeh S, Cammell G, Carey WD, et al. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001; 33(1):196-200. (Pubitemid 32016902)
110. Tine F, Caltagirone M, Camma C, et al. Clinical indicants of compensated cirrhosis: a prospective study. In: Gentilini P, ed. Chronic Liver Damage. Amsterdam, the Netherlands: Elsevier Science Publishers; 1990: 187-198. (Pubitemid 20232792)
111. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Gastroenterology. 1988;95(3):734-739.
112. Ikeda K, Saitoh S, Kobayashi M, et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Hepatol Res. 2000;18(3):252-266.
113. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests. Hepatology. 2005;42 (2):282-292. (Pubitemid 41061080)
114. Nanji AA, French SW, Mendenhall CL. Serum aspartate aminotransferase to alanine aminotransferase ratio in human and experimental alcoholic liver disease. Enzyme. 1989;41(2):112-115. (Pubitemid 19097728)
115. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2006;21(9):1459-1465. (Pubitemid 44154717)
116. Chrysanthos NV, Papatheodoridis GV, Savvas S, et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol. 2006;18(4):389-396.
117. Borroni G, Ceriani R, Cazzaniga M, et al. Comparison of simple tests for the noninvasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. Aliment Pharmacol Ther. 2006;24(5):797-804.
118. Nyblom H, Björnsson E, Simrén M, et al. The AST /ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int. 2006;26(7):840-845. (Pubitemid 44165252)
119. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107(9):2212-2222.
120. Snyder N, Gajula L, Xiao SY, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40(6):535-542. (Pubitemid 44318139)
121. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of noninvasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006;44(4):686-693.
122. Wong VW, Wong GL, Tsang SW, et al. Metabolic and histological features of nonalcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther. 2009; 29(4):387-396.
123. Shire NJ, Rao MB, Succop P, et al. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol. 2009; 7(4):471-480.
124. Castéra L, Le Bail B, Roudot-Thoraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C. J Hepatol. 2009;50(1):59-68.
125. Chang PE, Lui HF, Chau YP, et al. Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians. Aliment Pharmacol Ther. 2008;28(1):51-61.
126. Loko MA, Castera L, Dabis F, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients. Am J Gastroenterol. 2008;103(8):1973-1980.
127. Dinesen L, Caspary WF, Chapman RW, et al. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. Dig Liver Dis. 2008;40(9):743-748.
128. Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, et al. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver Int. 2008;28(4):486-493. (Pubitemid 351411134)
129. Ichino N, Osakabe K, Nishikawa T, et al. A new index for non-invasive assessment of liver fibrosis. World J Gastroenterol. 2010;16(38):4809-4816.
130. Westin J, Ydreborg M, Islam S, et al. A noninvasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol. 2008;43(1):73-80.
131. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining noninvasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2007;13(4): 525-531. (Pubitemid 46210918)
132. Fujii H, Enomoto M, Fukushima W, et al. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(6):608-614.
133. Bonnard P, Sombié R, Lescure FX, et al. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg. 2010;82(3):454-458.
134. Kim BK, Kim Y, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30 (4):546-553.
135. Nishikawa Y, Fukumoto K, Watanabe F. Clinical evaluation of serum guanase activity in liver diseases. Clin Biochem. 1984;17(5):327-330. (Pubitemid 14019782)
136. Zoli M, Magalotti D, Grimaldi M, Gueli C, Marchesini G, Pisi E. Physical examination of the liver. Am J Gastroenterol. 1995;90(9):1428-1432.
137. Carrion AF, Ghanta R, Carrasquillo O, Martin P. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol Hepatol. 2011; 9(10):834-841.
138. Theodossi A, Knill-Jones RP, Skene A, et al. Interobserver variation of symptoms and signs in jaundice. Liver. 1981;1(1):21-32. (Pubitemid 11015250)
139. Espinoza P, Ducot B, Pelletier G, et al. Interobserver agreement in the physical diagnosis of alcoholic liver disease. Dig Dis Sci. 1987;32(3):244-247. (Pubitemid 17054263)
140. Ahmad W, Ijaz B, Javed FT, et al. A comparison of four fibrosis indexes in chronic HCV. BMC Gastroenterol. 2011;11:44.
141. Sirli R, Sporea I, Bota S, Popescu A, Cornianu M. A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection. Hepat Mon. 2010;10(2):88-94.
142. Zhu X, Wang LC, Chen EQ, et al. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci. 2011;56(9):2742-2749.
143. Adams LA, George J, Bugianesi E, et al. Complex noninvasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26(10):1536-1543.
144. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Hepatology. 2007;46(1):32-36.
145. Saleh HA, Abu-Rashed AH. Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis. J Gastrointestin Liver Dis. 2007; 16(4):425-426.
146. de Bruyn G, Graviss EA. A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Med Inform Decis Mak. 2001;1:6.